World’s drugmaker Astrazeneca on Saturday 13, won a deal to supply upto 400 million doses of experimental COVID -19 vaccine to European countries.
The deal is among series of agreements as scientists, governments and pharmaceutical companies globally are speeding research to combat the virus.
The company is planning to begin delivering the vaccine to European countries by the end of this year under the agreement with the inclusive Vaccine Alliance, formed this month by France, Germany, Italy and Netherlands.
All other EU member states will have a chance to take part under the same terms as original alliance members.
The funding for the project is expected to be done by government.
“The deal is aimed at ensuring that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” Astrazeneca CEO Pascal Soriot said in a prepared statement.
Astrazeneca CEO Pascal Soriot
“With our European suply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.” He added.
Mr. Soroit also hinted that the company is in talks with Japan, Russia, China and Brazil.
The Anglo – Swedish company recently completed similar agreements with Britain, the US, The Coalition for Epidermic Preparedness Innovations, a public – private charitable partnership based in Norway, and Gavi Vaccine Alliance, another public – private partnership headquartered in Geneva, for 700 million doses.
The company is also targeting to produce 1 billion doses under a deal with Serum Institute of India.
The vaccine was developed by Oxford University’s Jenner Institute, working with Oxford vaccine Group.
Jenner Institute laboratories, old road campus Research Building University of Oxford, England, UK. |PHOTO COURTESY|
Testing of experimental COVID – 19 vaccine began in April with a studi involving over 1,000 healthy volunteers in Britain aged 18 – 55.